Table 2.
Serotype (outbreak strain/PFGE pattern) | Clinical specimens (n = 94) | Product from ill persons’ homes (n = 24) | Product from regulatory investigations (n = 40) |
---|---|---|---|
Newport | |||
JJPX01·1645/NewpXAI.0413 | 35 | 14 | 18 |
JJPX01·4815 | 1 | 0 | 1 |
NewpXAI.0416 | 0 | 1 | 0 |
NewpXAI.0418 | 1 | 0 | 0 |
NewpXAI.0423 | 1 | 0 | 0 |
NewpXAI.0424 | 1 | 0 | 0 |
Hartford | |||
JHAX01·0291/HartXAI.0038 | 24 | 4 | 1 |
HartXAI.0040 | 2 | 0 | 0 |
Oranienburg | |||
JJXX01·0027/OraniXAI.0006 | 6 | 0 | 0 |
OraniXAI.0005/OraniBNI.0007 | 3 | 0 | 1 |
OraniXAI.0005/OraniBNI.0073 | 1 | 0 | 0 |
OraniXAI.0005/OraniBNI.0075 | 1 | 0 | 0 |
Saintpaul | |||
SainXAI.0005/SainBNI.0073 | 14 | 1 | 2 |
SainXAI.0005/SainBNI.0010 | 1 | 1 | 0 |
Coinfections | |||
NewpXAI.0413 and HartXAI.0038 | 2 | 0 | 0 |
NewpXAI.0416 and HartXAI.0038 | 1 | 0 | 0 |
Additional serotypes/PFGE patterns* | – | 3 | 17 |